Repetition of continuous PTH treatments followed by periodic withdrawals exerts anabolic effects on rat bone.
Various animal experiments and human studies have shown that intermittent injections of parathyroid hormone (PTH) exert anabolic effects on bone, whereas continuous PTH treatment decreases the bone mass and causes hypercalcemia in animals. However, limited data are available with regard to the effects of a repetitive regimen of continuous treatments of PTH followed by periodic withdrawals on the bone metabolism. We investigated the effects of this regimen by comparing the findings of intermittent and continuous PTH treatments in rats. Infusions of PTH for 24 h followed by 6-day withdrawal periods from PTH transiently increased the serum calcium levels on day 1, but these levels were within the normocalcemic range. The repetition of 4 cycles of continuous PTH infusions followed by PTH withdrawals as well as intermittent PTH treatment increased the trabecular bone thickness, osteoblast surface, and bone formation rate. Continuous PTH infusions followed by PTH withdrawals also increased the cortical thickness of the femoral diaphysis and the osteoid volume in trabecular bones, whereas the continuous treatment failed to induce these changes. These findings suggest that continuous PTH treatment followed by PTH withdrawal is a potential regimen that can induce the anabolic effects of PTH in bone metabolism without inducing hypercalcemia.
Etoh
Masaya
M
Section of Oral Pathology, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8549, Japan.
Yamaguchi
Akira
A
D000818:Animals; D001696:Biomechanical Phenomena; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism*; D002118:Calcium / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D005269:Femur / Q000187:drug effects / Q000502:physiology; D005272:Femur Neck / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D019379:Teriparatide / Q000008:administration & dosage*; D013977:Tibia / Q000187:drug effects / Q000502:physiology
D019379:Teriparatide; D002118:Calcium
Drug Dev Ind Pharm. 2010 Jan;36(1):31-44
19640245
Bone. 2003 Sep;33(3):372-9
13678779
Endocrinology. 2001 Sep;142(9):4047-54
11517184
J Bone Miner Res. 2005 Oct;20(10):1792-803
16160737
Z Ernahrungswiss. 1998 Jun;37(2):183-9
9698646
Osteoporos Int. 2006 Jan;17(1):85-90
15981021
Bone. 1995 Apr;16(4):477-84
7605709
J Bone Miner Res. 1993 Sep;8(9):1097-101
8237479
Expert Opin Drug Deliv. 2005 Nov;2(6):993-1002
16296804
J Bone Miner Res. 2004 Jul;19(7):1165-71
15177000
N Engl J Med. 2001 May 10;344(19):1434-41
11346808
Bone. 2007 Jan;40(1):169-74
16876496
Bone. 1998 Sep;23(3):249-55
9737347
J Bone Miner Res. 2001 Oct;16(10):1846-53
11585349
J Bone Miner Res. 2009 Sep;24(9):1586-97
19419301
Endocrinology. 1988 Jun;122(6):2899-904
3371266
J Clin Endocrinol Metab. 2008 Jun;93(6):2166-72
18349061
J Bone Miner Res. 1987 Dec;2(6):595-610
3455637
Bone. 2000 Feb;26(2):175-82
10678413
J Pharm Sci. 2002 Feb;91(2):350-61
11835195
J Endocrinol. 2005 Sep;186(3):549-57
16135674
J Biol Chem. 2007 Nov 9;282(45):33098-106
17690108
Endocrinology. 1997 Nov;138(11):4607-12
9348185
J Bone Miner Res. 1994 Jan;9(1):59-67
8154310